UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
TCRX holding history
TScan Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
TCRX overviewAll 13F holders of TCRXFull Q2 2026 holdings
- Shares (Q2 2026)
- 68,873
- Value
- $67.5K
- % of portfolio
- <0.1%
- Quarters held
- 19
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 68,873 | $67.5K | <0.1% | +36,389+112.0% | Added | Holders |
| Q1 2026 | 32,484 | $32.8K | <0.1% | −22,714−41.2% | Reduced | Holders |
| Q4 2025 | 55,198 | $55.2K | <0.1% | +44,125+398.5% | Added | Holders |
| Q3 2025 | 11,073 | $20.2K | <0.1% | −389,328−97.2% | Reduced | Holders |
| Q2 2025 | 400,401 | $580.6K | <0.1% | +276,960+224.4% | Added | Holders |
| Q1 2025 | 123,441 | $170.3K | <0.1% | +31,581+34.4% | Added | Holders |
| Q4 2024 | 91,860 | $279.3K | <0.1% | +72,516+374.9% | Added | Holders |
| Q3 2024 | 19,344 | $96.3K | <0.1% | +6,699+53.0% | Added | Holders |
| Q2 2024 | 12,645 | $74.0K | <0.1% | +10,744+565.2% | Added | Holders |
| Q1 2024 | 1,901 | $15.1K | <0.1% | +477+33.5% | Added | Holders |
| Q4 2023 | 1,424 | $8.30K | <0.1% | +309+27.7% | Added | Holders |
| Q3 2023 | 1,115 | $2.85K | <0.1% | +15+1.4% | Added | Holders |
| Q2 2023 | 1,100 | $2.75K | <0.1% | −2,140−66.0% | Reduced | Holders |
| Q1 2023 | 3,240 | $6.80K | <0.1% | +2,240+224.0% | Added | Holders |
| Q4 2022 | 1,000 | $1.55K | <0.1% | −2,441−70.9% | Reduced | Holders |
| Q3 2022 | 3,441 | $11.0K | <0.1% | +2,293+199.7% | Added | Holders |
| Q2 2022 | 1,148 | $4.00K | <0.1% | +1,148 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −811−100.0% | Sold out | Holders |
| Q4 2021 | 811 | $4.00K | <0.1% | −135−14.3% | Reduced | Holders |
| Q3 2021 | 946 | $8.00K | <0.1% | +946 | New | Holders |